- Dana-Farber Cancer Institute and Astellas Pharma Inc. today announced a three-year collaboration to research and develop small molecule inhibitors of oncogenic K-Ras for the treatment of cancer, including lung cancer.
Tags: LungCancer, Partnerships
- David G. Nathan, MD, president emeritus of Dana-Farber Cancer Institute and physician-in-chief emeritus of Boston Children's Hospital, was honored as the inaugural recipient of the Boston Children’s Hospital Lifetime Impact Award at the hospital’s second Annual Global Pediatric Innovation Summit, Taking on Tomorrow (#PedInno14).
Tags: ChildhoodCancer, Honors
- Scientists have identified a genetic mutation in about 20 percent of colorectal and endometrial cancers that had been overlooked in recent large, comprehensive gene searches. With this discovery, the altered gene, called RNF43, now ranks as one of the most common mutations in the two cancer types.
Tags: ColonCancer, Genomics, GynecologicCancers
- Todd R. Golub, MD, Margaret A. Shipp, MD, and Bruce M. Spiegelman, PhD, of Dana-Farber Cancer Institute, have been elected to the Institute of Medicine (IOM), a nongovernmental organization that advises the nation on issues related to biomedical science, medicine, and health.
Tags: Appointments, Honors
- Daphne A. Haas-Kogan, MD, has been appointed chair of the Department of Radiation Oncology at Dana-Farber/Brigham and Women's Cancer Center (DF/BWCC) effective July 1, 2015, and will be appointed professor at Harvard Medical School. She will also be the Endowed Professor of Radiation Oncology at Brigham and Women’s Health Care.
Tags: Appointments, Radiation
- The Centers for Disease Control and Prevention’s (CDC) Division of Cancer Prevention and Control (DCPC) has awarded a $1.75 million 5 year grant to the Program for Young Women with Breast Cancer at Dana-Farber Cancer Institute to increase the awareness of breast cancer among women and enhance the support services for those diagnosed and treated. The Program for Young Women with Breast Cancer at Dana-Farber was one of only seven organizations to be awarded this competitive grant.
Tags: BreastCancer, Grants
- Dana-Farber is part of a select group of healthcare facilities nationwide to be named Leaders in LGBT Healthcare Equality by the Human Rights Campaign Foundation.
- As more terminally ill patients choose to spend their final days and weeks in hospice care rather than a hospital, the hope is the use of intensive and costly hospital services would decline. A new study by Dana-Farber Cancer Institute researchers shows for one group of terminally ill cancer patients, that is not what is happening.
Tags: EndOfLife, OvarianCancer
- A new study by researchers at Dana-Farber Cancer Institute shows a half-day educational program can help women successfully deal with side effects of ovary removing surgery as a cancer prevention measure.
Tags: OvarianCancer, Genetics
- A new form of gene therapy for boys with X-linked severe combined immunodeficiency syndrome (SCID-X1) — "bubble boy" disease — appears to be both effective and safe, researchers from Dana-Farber/Boston Children’s Cancer and Blood Disorders Center and collaborating institutions report in the New England Journal of Medicine.
Showing 21-30 of 557 items